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ABSTRACT
Objectives: Acquired severe aplastic anaemia is a rare
and potentially fatal disease. The aim of this Cochrane
review was to evaluate the effectiveness and adverse
events of first-line allogeneic haematopoietic stem cell
transplantation of human leucocyte antigen (HLA)-
matched sibling donors compared with first-line
immunosuppressive therapy.
Setting: Specialised stem cell transplantations units in
primary care hospitals.
Participants: We included 302 participants with
newly diagnosed acquired severe aplastic anaemia. The
age ranged from early childhood to young adulthood.
We excluded studies on participants with secondary
aplastic anaemia.
Interventions: We included allogeneic haematopoietic
stem cell transplantation as the test intervention
harvested from any source of matched sibling donor
and serving as a first-line therapy. We included
immunosuppressive therapy as comparator with either
antithymocyte/antilymphocyte globulin or ciclosporin
or a combination of the two.
Primary and secondary outcome measures
planned and finally measured: The primary
outcome was overall mortality. Secondary outcomes
were treatment-related mortality, graft failure,
graft-versus-host disease, no response to
immunosuppressive therapy, relapse after initial
successful treatment, secondary clonal disease or
malignancies, health-related quality of life and
performance scores.
Results: We identified three prospective non-
randomised controlled trials with a study design that
was consistent with the principle of ‘Mendelian
randomisation’ in allocating patients to treatment
groups. All studies had a high risk of bias due to the
study design and were conducted more than 15 years.
The pooled HR for overall mortality for the donor
group versus the no donor group was 0.95 (95% CI
0.43 to 2.12, p=0.90).
Conclusions: There are insufficient and biased data
that do not allow any firm conclusions to be made
about the comparative effectiveness of first-line
allogeneic haematopoietic stem cell transplantation of
HLA-matched sibling donors and first-line
immunosuppressive therapy of patients with acquired
severe aplastic anaemia.
INTRODUCTION
Acquired severe aplastic anaemia (SAA) is a
rare1 and potentially fatal disease which is
characterised by hypocellular bone marrow
and pancytopenia; it mainly affects young
adults. The estimated incidence rate of SAA
ranges from 0.7 to 4.1 per million people
Strengths and limitations of this study
▪ We conducted a comprehensive literature search
and strictly adhered to the projected
methodology.
▪ We restricted the study design to randomised
controlled trials and prospective non-randomised
controlled trials and the studies had to be com-
patible with ‘Mendelian randomisation’ to avoid
excess risk of bias.
▪ The included data are too scarce and too biased
to allow any conclusion on the comparative
effectiveness of matched sibling donor-
haematopoietic stem cell transplantation and
immunosuppressive therapy.
▪ The included data were collected 15 to more
than 30 years ago. Thus, the results may not be
applicable to current modern standard care.
iThis article is based on a Cochrane Systematic Review
published in the Cochrane Database of Systematic
Reviews 2013, Issue 7. Art. No.: CD006407. DOI:
10.1002/14651858.CD006407.pub2. (see http://www.
thecochranelibrary.com for information). Cochrane
Systematic Reviews are regularly updated as new
evidence emerges and in response to feedback, and the
CDSR should be consulted for the most recent version
of the review.
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per year.2 The underlying pathophysiology is thought to
be an aberrant immune response involving the
T-cell-mediated destruction of haematopoietic stem
cells.3 Major signs and symptoms are severe infections,
bleeding and exhaustion and patients may experience
paleness, weakness, fatigue and shortness of breath.
According to the 2009 Guidelines for the diagnosis
and management of aplastic anaemia of the British
Committee for Standards in Haematology,4 ﬁrst-line allo-
geneic haematopoietic stem cell transplantation (HSCT)
from the bone marrow of an human leucocyte antigen
(HLA)-matched sibling donor (MSD) is regarded as the
initial treatment of choice for newly diagnosed patients
with SAA. Graft failure may lead to early death and the
conditioning regimen may lead to severe non-
haematological organ toxicities.
According to the 2009 Guidelines for the diagnosis and
management of aplastic anaemia of the British Committee
for Standards in Haematology,4 ﬁrst-line immunosuppres-
sive therapy (IST) is a combination of antithymocyte
globulin (ATG) and ciclosporin. First-line IST is indicated
for patients where no MSD is available, which can be
expected for 70% of patients with SAA.3 Ciclosporin is an
immunosuppressant drug that is not lymphocytotoxic but
has speciﬁc inhibitory effects on T-lymphocyte function.5
In the past, antilymphocyte globulin (ALG) was reported
interchangeably in the literature alongside ATG, therefore,
ALG is reported in the present study on equal terms. ATG
as well as ALG are polyclonal antibodies that recognise a
variety of human lymphocyte cell surface antigens, reduce
the number of lymphocytes and induce an immunosup-
pressive effect. They originate in animals immunised with
either normal human thymocytes, collected at paediatric
cardiac surgery or thoracic duct lymphocytes, collected
during therapeutic cannulation.5 Concerning the haem-
atological response and the survival of patients after a ﬁrst
treatment for SAA, it may be crucial in what type of animal
ATG originates, as a randomised study showed that rabbit
ATG was inferior in this respect to horse ATG.6 The cur-
rently recommended combination of ciclosporin with
ATG in the treatment of SAA is based on their separate
and potentially complementary modes of action.5 Some
patients do not respond well to ISTor show no response at
all. Frequent transfusions increase the risk of adverse
events such as iron overload and early death. If a diagnosis
of SAA is established at an early patient age, then it is
crucial to know which treatment promises more beneﬁt
and less harm in the long run. We aimed to evaluate the
effectiveness and severe adverse events of MSD-HSCTcom-
pared with IST in patients with SAA.
METHODS
This article is based on a Cochrane Systematic Review
published in The Cochrane Library.7 Publication of this
work is in agreement with the policy of The Cochrane
Collaboration.8 While preparing this systematic review
and meta-analysis, we endorsed the PRISMA statement,
adhered to its principles and conformed to its checklist.9
Study inclusion criteria
We included randomised controlled trials (RCTs) and
prospective non-RCTs as long as the study design was con-
sistent with the principle of ‘Mendelian randomisation’
in allocating patients to treatment groups. We required a
minimum of 80% of relevant patients per group and we
set a minimum sample size of ﬁve participants per group.
We set no limits on language, year of publication or year
of treatment. We included participants with newly diag-
nosed acquired SAA.4 We did not set any age limits for
participants. We excluded studies on participants with
secondary aplastic anaemia. We included HSCT as the
test intervention harvested from any source of MSD and
serving as a ﬁrst-line therapy.10 That means, no other
HSCT or IST has been offered to the patients before. We
included IST as comparator with ciclosporin combined
with ATG as the current mode of IST.10 To accommodate
former modes of IST, we also included ciclosporin com-
bined with ALG, cyclosporine alone, ATG alone and
ALG. Other agents such as corticosteroids and androgens
were not considered. The primary outcome was overall
mortality. Secondary outcomes were treatment-related
mortality, graft failure, graft-versus-host disease, no
response to IST, relapse after initial successful treatment,
secondary clonal disease or malignancies, health-related
quality of life and performance scores.
Principle of ‘Mendelian randomisation’
There are ethical concerns around randomisation of
patients with SAA to transplantation versus non-
transplantation because the risk of early death is
expected to be higher in the transplantation group than
in the non-transplantation group. The reason is the
potentially life-threatening graft-versus-host disease
occurring only in the transplanted patients. Gray11 and
Wheatley12 described the potential of ‘Mendelian ran-
domisation’ to minimise bias when comparing
MSD-HSCT with an alternative therapy. The base
concept has been ascribed to Katan.13 ‘Mendelian ran-
domisation’ means the view that nature itself has already
‘randomised’ the paternal and maternal part of a gene
given that donor and recipient are siblings. Thus,
‘Mendelian randomisation’ by deﬁnition accepts only
siblings as transplant donors and these sibling donors
are required to have ‘identical’ or matched features of
speciﬁc transplant-relevant HLA sites when compared
with the transplant recipient. Therefore, patients with
an HLA-matched sibling will be allocated to the
MSD-HSCT group. On the other hand, patients with sib-
lings that are not HLA compatible will be allocated to
the IST group. The term ‘Mendelian randomisation’
refers to the fact that the genetic distribution of paternal
and maternal alleles follows a random process and is
determined before birth. This concept takes advantage
of an instrumental variable for allocating the patients to
2 Peinemann F, et al. BMJ Open 2014;4:e005039. doi:10.1136/bmjopen-2014-005039
Open Access
treatment groups and, at the same time, this variable is
neither associated with the treatment nor associated
with the outcome.
Search strategy and selection of studies
We conducted an electronic literature database search
in MEDLINE (Ovid), EMBASE (Ovid), and Cochrane
Library CENTRAL (Wiley) including articles published
from inception to 22 April 2013. The corresponding
search strategies are depicted in the original Cochrane
Review.7 We retrieved all titles and abstracts by electronic
searching and downloaded them to the reference man-
agement database EndNote Version X3.14 Two authors
assessed the eligibility of retrieved papers independently.
We considered studies written in languages other than
English. We judged studies to be prospective if an expli-
cit statement was reported or there were clues suggesting
a prospective design (eg, prior approval of treatment
and informed consent). We judged studies to be retro-
spective if an explicit statement was reported or it was
implied by description that data were reviewed from an
existing source. We regarded each of the following items
as an indication of a retrospective design: registry
reports and reviewing of medical records. We judged
studies as consistent with the principle of ‘Mendelian
randomisation’ if all transplant donors were clearly sib-
lings and if the allocation of patients to treatment
groups was not based on age. We regarded studies as not
consistent with the principle of ‘Mendelian randomisa-
tion’ if age was not balanced between groups, indicating
that age played a role in the group assignment. Example
for imbalance: distribution of age categories was statistic-
ally not comparable (p value less than 0.05).
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of
bias in the included studies using six criteria. We have
used four criteria from The Cochrane Collaboration’s
tool for assessing risk of bias15: blinding of outcome
assessment, complete outcome data such as missing
data, selective reporting such as not reporting prespeci-
ﬁed outcomes and other sources of bias such as bias
related to the speciﬁc study design and competing inter-
est. We extended the Cochrane tool for assessing risk of
bias with two additional criteria that are speciﬁc to the
inclusion criteria for the present review and critical for
conﬁdence in results: comparable baseline character-
istics and concurrent control. We applied The Cochrane
Collaboration’s criteria for judging risk of bias.16
Data synthesis
One review author entered the data into Review
Manager.17 Another review author checked the entered
data. We synthesised data on mortality for the donor
group (MSD-HSCT) versus the no donor group (IST) by
using the HR for time-to-event data as the primary effect
measure with a random-effects model. If the HR was not
directly given in the publication, we estimated HRs
according to methods proposed by Parmar et al18 and
Tierney et al.19
RESULTS
Search results
We identiﬁed three non-randomised, prospective, paral-
lel and controlled clinical trials (ﬁgure 1). Bayever et al20
and Gratwohl et al21 reported their results in a single ori-
ginal article, respectively. Führer et al22 reported ﬁve
Figure 1 Study flow (IST,
first-line immunosuppressive
therapy; MSD-HSCT, first-line
allogeneic haematopoietic stem
cell transplantation of bone
marrow of HLA-matched sibling
donors; ‘MR’, ‘Mendelian
randomisation’; SAA, acquired
severe aplastic anaemia.
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publications including one original article, a follow-up
article, 23 one protocol 24 and two abstracts. 25 26 We did
not identify any RCTs.
Characteristics of included articles
The main study, patients and interventions character-
istics are shown in table 1. The patients were treated and
observed between 1976 and 1997. Thus, the reported
data were collected more than 15 years ago. Median
follow-up was not reported. Median age, fraction of
males and median days of time interval between diagno-
sis and begin of treatment were roughly comparable
between the treatment groups within each study. The
age ranged from early childhood to young adulthood.
In the study by Führer et al,22 all patients were less than
17 years old by deﬁnition of the inclusion criteria. Bone
marrow was used as the source for all transplants. All
three included studies had a high risk of bias due to the
study design (table 2). We judged a low risk of bias for
blinding the assessment of overall mortality. Blinding or
lack of blinding is not expected to make a difference
concerning overall mortality. The authors of all included
studies did not report that ‘Mendelian randomisation’
was planned and the authors did not report the size of
the involved families. The authors did not report the
numbers of siblings and the results of the individual
genetic analyses.
Effects of intervention
The pooled HR estimate for overall mortality was 0.95
with a 95% CI of 0.43 to 2.12 (p=0.90; ﬁgure 2).
According to the meta-analysis based on data from all
three included studies, overall mortality was not statistic-
ally signiﬁcantly different between MSD-HSCT and IST.
Overall survival ranged from 47% to 84% in the
MSD-HSCT group and from 45% to 87% in the IST
group (table 3). The results for the secondary outcomes
including treatment-related mortality after MSD-HSCT,
graft failure after MSD-HSCT, graft-versus-host-disease
(GVHD) after MSD-HSCT, no response to IST and
relapse after IST are shown in table 4. With respect to
secondary clonal disease or malignancies, Bayever et al20
reported one patient who developed T-cell lymphoma
after MSD-HSCT and Führer et al22 reported four
patients who developed acute myelogenous leukaemia
after IST. Health-related quality of life questionnaires
were not used in any of the included studies. Bayever
et al20 reported that almost all evaluable patients in the
MSD-HSCT group (92%) and less than half of the
patients in the IST group had a Karnofsky Performance
Status of higher than 70%.
DISCUSSION
Interpretation of main results
We identiﬁed three prospective, non-RCTs20–22 including
302 participants; 121 received MSD-HSCT and 181
received IST. On the basis of these trials we found
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insufﬁcient evidence to clarify whether MSD-HSCT
leads to better overall survival than IST. Overall survival
ranged from 47% to 84% in the MSD-HSCT group and
from 45% to 87% in the IST group and in a
meta-analysis, overall mortality was not statistically signiﬁ-
cantly different between the treatment groups.
Treatment-related mortality in the MSD-HSCT group
was considerable ranging from 20% to 42%. The graft
failure rate was variable and caused the death of 3% to
16% of transplanted patients. GVHD affected a quarter
to a half of transplanted patients. More than half of the
patients in one study did not respond to IST. Relapse
affected up to one in eight patients after IST in one
study. Secondary clonal disease or malignancies were
detected rarely in both treatment groups. Marsh et al4
estimated that allogeneic bone marrow transplantation
from an HLA-identical sibling donor provides a 75–90%
chance of long-term cure in patients younger than
40 years of age. Similarly, in a review of studies with
younger patients, Guinan27 reported an overall survival
between 75% and 95% at 3–5 years. Sangiolo et al28 con-
cluded that their data favours extending MSD-HSCT to
patients older than 40 years of age who are without sig-
niﬁcant comorbidities. The results of the studies
included in the present systematic review appear to
roughly match the recent estimates reported by others.
Recent therapeutic improvement
Bacigalupo (2008)29 reported that the outcome has
improved since 1996 for HSCT but not for IST.
Peinemann et al30 identiﬁed three studies that reported
a statistically signiﬁcant improvement of overall survival
in the group of matched related donor transplants but
not in the IST group. Several factors may have contribu-
ted to recent improvements in HSCT, such as detailed
HLA-matching and less irradiation-based conditioning.
The Third Consensus Conference on the treatment of
aplastic anaemia agreed in 2010 that bone marrow
should be used as the source of stem cells and that the
upper age limit should be 50 years and that the combin-
ation of ATG and ciclosporin remains the gold standard
for IST.31 Scheinberg32 provided an overview and update
of various treatment options for SAA including IST and
transplantation.
Strengths and limitations
One of the strengths of this review is the broadness of
the search strategy such that study retrieval bias is very
unlikely. We restricted the inclusion of studies to RCTs
and prospective non-RCTs that were compatible with
‘Mendelian randomisation’ to avoid excess risk of bias.
We assumed a possible ‘Mendelian randomisation’ in
the three included studies, though, the authors did not
Table 2 Risk of bias of included studies
Study ID
Blinding of
assessment of
overall
mortality
Incomplete
outcome
data
Selective
reporting
Other
bias
Comparable
baseline
characteristics
Concurrent
control
Overall
judgement
of bias
Bayever et al 20 Low Low Unclear High* Low Low High
Führer et al 22 Low High High† High‡ Low Low High
Gratwohl et al 21 Low High Unclear Unclear Low Low High
*Bayever et al 20: the authors reported the study results at an early time point before all planned data had been gathered: ‘We present this
interim report (…)’.
†Führer et al 22: In the 2005 update, overall survival, secondary clonal disease or malignancies, and also relapse were not reported separately
for the two distinct treatment groups. Rather, the results were presented for two subgroups according to disease severity. This was different
from the earlier report of the same study published in 1998 covering the study period from 1993 to 1997. See figure 1 and table 1 of the
article.
‡Führer et al 22: financial support was provided by two pharmaceutical companies.
Figure 2 Mortality in the donor group (MSD-HSCT) versus the no donor group (IST); effect: HR; random-effects model. SE
calculated from data presented in the Kaplan-Meier graph of the article (MSD-HSCT, first-line allogeneic haematopoietic stem cell
transplantation of bone marrow of HLA-matched sibling donors; log, logarithm; IST, first-line immunosuppressive therapy;
IV, inverse variance).
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mention this approach and did not report what propor-
tion of patients with an MSD actually received the trans-
plant. Thus, crucial information is lacking to judge the
compliance of patients and the signiﬁcance of the
assumed concept of natural allocation. Nevertheless,
the included data are too scarce and too biased to allow
any conclusion on the comparative effectiveness of
MSD-HSCT and IST. The rates of adverse events, such as
treatment-related mortality, graft failure, no response to
IST and GVHD, are unusually high, which may be
explained by the age of the studies (starting in 1976).
We did not separate horse ATG from rabbit ATG,
although the type of animal as the origin of ATG was
reported as a serious effect modiﬁer.6 All data were col-
lected about 15 up to more than 30 years ago. Thus, the
results may not be applicable to current modern stand-
ard care. Use of ‘Mendelian randomisation’ is no guar-
antee that bias is minimised. This may be because tissue
typing data may not be accurate. Patients may have only
one sibling either in the donor or in the no donor
group. Large families have a greater chance of ﬁnding a
donor. Therefore, designing a non-RCT by applying
‘Mendelian randomisation’ requires careful thought to
effectively reduce bias and control for potential con-
founders. There is a time lag in patients with siblings
because tissue typing and readiness for assignment to
treatment group may possibly take several months.12 On
the other hand, patients with no siblings can be assigned
immediately and are at earlier risk for adverse events.
Nitsch et al33 described the limits to causal inference
based on ‘Mendelian randomisation’.
CONCLUSIONS
There are insufﬁcient and biased data that do not allow
any ﬁrm conclusions to be made about the comparative
effectiveness of MSD-HSCT and IST. Patients should be
made aware of the early treatment-related mortality and
the burden of GVHD after HSCT. Patients treated with
IST should also be made aware that the disease may
recur after initial successful treatment, and that life-
threatening late clonal and malignant disease after IST
may occur in a higher percentage compared with HSCT.
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Table 3 Overall survival
Study ID
Donor group (MSD-HSCT) No donor group (IST) FU*
p ValueN OS (95% CI), % N OS (95% CI), % Year
Bayever et al 20 35 72 (64 to 80) 22 45 (29 to 61) 2 0.18
Führer et al 22 28 84 (NR) 86 87 (NR) 4 0.43
Gratwohl et al 21 19 47 (NR) 13 69† (NR) 5 0.56‡
*Time point of Kaplan-Meier estimate.
†Gratwohl et al 21: 2 of 13 patients were eligible for MSD-HSCT but donors were not available in the first place; the two patients died after
they received a second-line HSCT from the then again available MSD that was offered after the patients showed no response to IST.
‡The p value was not reported and we calculated the p value using Fisher’s exact test.
FU, follow-up; IST, immunosuppressive therapy including ciclosporin and/or antithymocyte or antilymphocyte globulin; MSD-HSCT, first-line
allogeneic haematopoietic stem cell transplantation from HLA-matched sibling donor; N, number of analysed patients; NR, not reported; OS,
overall survival.
Table 4 Secondary outcomes
Study ID|
TRM after
MSD-HSCT*†
Graft failure after
MSD-HSCT*
GVHD after
MSD-HSCT*
No response
to IST*
Relapse at
5 years after IST*
Bayever et al 20 20% (7 of 35) 3% (1 of 35) 51% (17 of 33) 64% (14 of 22) 12.5% (1 of 8)
Führer et al 22 NR NR NR NR NR
Gratwohl et al 22 42% (8 of 19) 16% (3 of 19) 26% (5 of 19) 15% (2 of 13) NR
*In parenthesis: number of affected of number of evaluable patients.
†Treatment-related mortality was not reported for IST.
GVHD, graft-versus-host disease; IST, immunosuppressive therapy including ciclosporin and/or antithymocyte or antilymphocyte globulin;
MSD-HSCT, first-line allogeneic haematopoietic stem cell transplantation from HLA-matched sibling donor; NR, not reported; TRM,
treatment-related mortality.
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